Free Trial

Genenta Science (GNTA) Competitors

Genenta Science logo
$3.87 0.00 (-0.03%)
As of 07/3/2025 12:31 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

GNTA vs. TVGN, BTMD, INBX, DSGN, ESPR, NBTX, MDWD, CRDF, IMAB, and PRQR

Should you be buying Genenta Science stock or one of its competitors? The main competitors of Genenta Science include Semper Paratus Acquisition (TVGN), biote (BTMD), Inhibrx Biosciences (INBX), Design Therapeutics (DSGN), Esperion Therapeutics (ESPR), Nanobiotix (NBTX), MediWound (MDWD), Cardiff Oncology (CRDF), I-Mab (IMAB), and ProQR Therapeutics (PRQR). These companies are all part of the "pharmaceutical products" industry.

Genenta Science vs. Its Competitors

Semper Paratus Acquisition (NASDAQ:TVGN) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

Semper Paratus Acquisition has a beta of -0.73, indicating that its stock price is 173% less volatile than the S&P 500. Comparatively, Genenta Science has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500.

Semper Paratus Acquisition presently has a consensus target price of $10.00, indicating a potential upside of 703.21%. Genenta Science has a consensus target price of $25.00, indicating a potential upside of 546.16%. Given Semper Paratus Acquisition's higher probable upside, analysts plainly believe Semper Paratus Acquisition is more favorable than Genenta Science.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Semper Paratus Acquisition
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Genenta Science
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Semper Paratus Acquisition had 1 more articles in the media than Genenta Science. MarketBeat recorded 3 mentions for Semper Paratus Acquisition and 2 mentions for Genenta Science. Semper Paratus Acquisition's average media sentiment score of 0.62 beat Genenta Science's score of 0.00 indicating that Semper Paratus Acquisition is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Semper Paratus Acquisition
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Genenta Science
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Semper Paratus AcquisitionN/AN/A-$13.73MN/AN/A
Genenta ScienceN/AN/A-$9.64MN/AN/A

15.1% of Genenta Science shares are owned by institutional investors. 73.2% of Semper Paratus Acquisition shares are owned by company insiders. Comparatively, 29.0% of Genenta Science shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Semper Paratus AcquisitionN/A N/A -934.56%
Genenta Science N/A N/A N/A

Summary

Semper Paratus Acquisition and Genenta Science tied by winning 4 of the 8 factors compared between the two stocks.

Get Genenta Science News Delivered to You Automatically

Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GNTA vs. The Competition

MetricGenenta ScienceMED IndustryMedical SectorNASDAQ Exchange
Market Cap$70.78M$2.91B$5.53B$8.95B
Dividend YieldN/A2.42%5.38%4.09%
P/E RatioN/A21.5627.4020.24
Price / SalesN/A277.33417.66125.07
Price / CashN/A41.9536.6357.47
Price / Book5.237.518.085.67
Net Income-$9.64M-$55.05M$3.16B$248.47M
7 Day Performance24.81%4.59%2.81%3.29%
1 Month Performance-11.26%4.86%3.69%5.18%
1 Year PerformanceN/A5.82%35.30%21.35%

Genenta Science Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GNTA
Genenta Science
1.9081 of 5 stars
$3.87
0.0%
$25.00
+546.2%
+25.2%$70.78MN/A0.007
TVGN
Semper Paratus Acquisition
4.0025 of 5 stars
$1.16
-3.3%
$7.10
+512.1%
+81.5%$220.67MN/A0.003
BTMD
biote
2.7088 of 5 stars
$4.01
+1.3%
$8.00
+99.5%
-43.1%$216.65M$197.19M6.57194
INBX
Inhibrx Biosciences
1.2603 of 5 stars
$14.56
-2.5%
N/A+21.2%$216.12M$200K0.12166
DSGN
Design Therapeutics
0.4025 of 5 stars
$3.90
+4.3%
$4.00
+2.6%
+18.2%$212.32MN/A-3.9440
ESPR
Esperion Therapeutics
4.1547 of 5 stars
$1.04
-2.8%
$7.00
+573.1%
-50.4%$212.07M$332.31M-1.30200
NBTX
Nanobiotix
1.7231 of 5 stars
$4.45
-0.5%
$8.00
+79.8%
-7.1%$210.68M-$11.61M0.00100Positive News
Gap Up
MDWD
MediWound
1.6644 of 5 stars
$18.99
-0.5%
$31.80
+67.5%
+34.2%$206.32M$20.22M-9.0980
CRDF
Cardiff Oncology
1.6497 of 5 stars
$3.16
+1.9%
$12.00
+279.7%
+62.5%$206.23M$680K-3.4320
IMAB
I-Mab
3.1049 of 5 stars
$2.46
-1.6%
$5.50
+123.6%
+48.7%$204.15M$3.89M0.00380Gap Up
PRQR
ProQR Therapeutics
2.1894 of 5 stars
$1.95
+1.0%
$8.00
+310.3%
+30.7%$203.06M$20.46M-5.57180News Coverage

Related Companies and Tools


This page (NASDAQ:GNTA) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners